business
Laplace Announces FDA IDE Approval of TRIUMPH Pivotal Trial of Its Transcatheter Tricuspid Valve Replacement System
By By Laplace Interventional, Inc. at Denton Record-Chronicle
· June 29, 2026
· 1 min read
MINNEAPOLIS, June 29, 2026 /PRNewswire/ -- Laplace Interventional today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company's pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.
Key takeaway Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company's pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.
Why this matters in Denton News
The FDA's approval of Laplace Interventional's Investigational Device Exemption for the TRIUMPH pivotal trial has implications for the medical device industry in the Dallas-Fort Worth area, where Denton is located. As a hub for medical innovation and research, the region is home to numerous companies and institutions involved in the development of cutting-edge medical technologies. The approval of Laplace's TTVR system trial could attract attention and investment to the area, potentially creating new opportunities for collaboration and job growth. Furthermore, the success of this trial could also lead to improved treatment options for patients with tricuspid valve disease in Denton and surrounding communities, who may have access to the latest medical advancements through local healthcare providers. The trial's progress will be worth monitoring to see how it may benefit the local medical community and economy.
About this story
Original reporting by Denton Record-Chronicle . Denton News surfaces reporting from trusted publishers and adds local editorial context so readers can quickly understand what a story means for their community. We attribute every source, link to the original report, and follow a documented editorial standards policy. To understand how stories are selected and reviewed, read our about page .
For the complete original report, visit Denton Record-Chronicle . Have a tip or correction? Contact our newsroom .
Category: business ·
Published: June 29, 2026 ·
Source: Denton Record-Chronicle ·
Reading time: 1 min
Get more Denton News stories like this
Free weekly briefing covering business and other local news. Curated by our editorial team. No spam.
By subscribing you agree to our privacy policy . Unsubscribe anytime.
Frequently asked about this story
What is this story about? MINNEAPOLIS, June 29, 2026 /PRNewswire/ -- Laplace Interventional today announced that the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) for TRIUMPH, the company's pivotal trial evaluating its Transcatheter Tricuspid Valve Replacement (TTVR) system.
When was this published? This article was first published on June 29, 2026 by Denton Record-Chronicle and curated for Denton News readers.
Who reported this story? This story was reported by By Laplace Interventional, Inc. at Denton Record-Chronicle. To learn more about how Denton News selects and reviews stories, see our editorial standards .
Where can I find related coverage? See more business coverage from Denton News, or browse our daily briefing and topic hubs .
← Back to all news
More business →
Today’s briefing
Subscribe to newsletter